November 18, 2026
Health news, explained with evidence
LIVE

FDA Clears New Oral Therapy for Advanced Breast Cancer

🧠 Mind & Mental Health 2 min read 👁 4

Federal regulators have approved giredestrant paired with everolimus for specific types of advanced breast cancer following positive clinical trial data.

FDA Clears New Oral Therapy for Advanced Breast Cancer🧠Mind & Mental Health

Photo: medpagetoday.com

Key points

  • FDA approved giredestrant combined with everolimus for advanced breast cancer
  • Phase III trial showed median progression-free survival nearly doubled in patients with ESR1 mutations
  • Companion diagnostic assay authorized to identify eligible patients with specific genetic profiles

The U.S. Food and Drug Administration has granted approval to giredestrant, marketed as Wilserdly, to be used alongside everolimus for treating adults with estrogen receptor-positive, HER2-negative, ESR1-mutated breast cancer that has progressed despite prior therapies. This all-oral treatment regimen is specifically indicated for individuals facing locally advanced or metastatic disease who experienced recurrence during or after endocrine adjuvant therapy, or following at least one previous endocrine regimen in a metastatic setting.

Approval stems from the global phase III evERA trial, which contrasted the giredestrant combination against standard endocrine therapy paired with everolimus. Data from participants with ESR1-mutated cancer revealed that median progression-free survival expanded significantly from 5.5 months under standard care to 10.0 months using the new combination. For the broader trial cohort, median progression-free survival reached 8.8 months with the giredestrant regimen.

Potential Side Effects and Safety Warnings

Commonly observed adverse events tied to the regimen included stomatitis, fatigue, rash, diarrhea, musculoskeletal pain, nausea, and pneumonitis. Additionally, frequent laboratory abnormalities involved decreases in hemoglobin, lymphocytes, white blood cells, neutrophils, platelets, calcium, potassium, and sodium, alongside elevated levels of aspartate transaminase, alanine transaminase, and creatinine. The official prescribing information also highlights specific warnings regarding embryo-fetal toxicity and bradycardia.

Alongside the drug approval, the agency cleared the FoundationOne Liquid CDx assay to serve as a companion diagnostic tool for detecting ESR1 mutations in breast cancer patients. What to know: While clinical trials suggest improved disease control, patients should consult their healthcare providers to evaluate personal treatment risks and benefits.

As oncologists we are always looking for better and more effective treatments for patients with metastatic breast cancer, particularly when their disease progresses on endocrine therapies and CDK4/6 inhibitors. - Dr. Erica Mayer, Dana-Farber Cancer Institute

Source medpagetoday.com — medpagetoday.com/hematologyoncology/breastcancer/123915 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.